No Data
No Data
Express News | The opening of the tenth batch of national Pharmaceutical centralized purchasing has prompted nearly 30 listed companies to announce their products are likely to be selected after the market close.
Express News | Fuyuan Pharmaceutical: The company's product, Losartan Hydrochlorothiazide Tablets, is set to be selected in the tenth batch of national centralized Pharmaceutical procurement.
Fuyuan Pharmaceutical (601089.SH): Participating in the tenth batch of national Pharmaceutical centralized procurement is expected to be selected.
On December 13, Gelonghui reported that Fuyuan Pharmaceutical (601089.SH) announced that on December 12, 2024, the company participated in the bidding work for the tenth batch of national centralized pharmaceutical procurement organized by the National Joint Procurement Office (hereinafter referred to as "Joint Procurement Office"). After opening and evaluating the bids by the Joint Procurement Office, the company's product, azilsartan and hydrochlorothiazide tablets, is expected to win the bid for this centralized procurement. The selection of supply provinces for azilsartan and hydrochlorothiazide tablets has been based on market potential in each province, and the results will be officially released after being announced by the Joint Procurement Office.
Beijing Foyou Pharma Gets Drug Registration for Mesalazine Capsules
Fosun Pharma (601089.SH): Mesalazine Enteric-Coated Sustained-Release Capsules Obtains Pharmaceutical Registration Certificate
Fuyuan Pharmaceutical (601089.SH) announced that recently, the company received the approval from the National Pharmaceutical Administration for the...
Express News | Fuyuan Pharmaceuticals: Mesalazine enteric-coated sustained-release capsules have obtained the pharmaceutical registration certificate.
No Data